A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety
Subject incidence of adverse events, dose limiting toxicities, and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests
36 months
Yes
MD
Study Director
Amgen
United States: Institutional Review Board
20120106
NCT01723020
November 2012
June 2015
Name | Location |
---|---|
Greenville Hospital System | Greenville, South Carolina 29605 |
Research Site | Danbury, Connecticut |
Research Site | Charleston, South Carolina |